FREM1: A Potential Drug Target and Biomarker for Cancer (G158326)

Target Name: FREM1

NCBI ID: G158326

FREM1

FREM1: A Potential Drug Target and Biomarker for Cancer

FREM1 (FREM1_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, and liver. It is a key regulator of cell division and has been implicated in the development and progression of various diseases, including cancer . In this article, we will discuss the FREM1 protein, its functions, potential drug targets, and its potential as a biomarker for certain diseases.

FREM1 Proteins

FREM1 is a member of the T-cell nuclear factor of the superfamily (TNFSF) and is expressed in a variety of tissues, including the brain, heart, liver, and pancreas. It is a 21-kDa protein that consists of 118 amino acid residues. FREM1 has been shown to play a role in regulating cell division and cell signaling pathways.

FREM1 has been shown to be involved in the regulation of cell proliferation and cell cycle progression. It has been shown to promote the G1 phase of the cell cycle and to inhibit the G2 phase. This means that FREM1 helps to control the growth and division of cells.

FREM1 has also been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed. This is important for the development of new blood vessels, which is critical for the delivery of oxygen and nutrients to tissues and for the removal of waste products.

Potential Drug Targets

FREM1 is a protein that has been shown to be involved in various diseases, including cancer. Therefore, it is a potential drug target for cancer treatment. Researchers have identified several potential drug candidates that target FREM1, including small molecules, antibodies, and vectors. These drugs have the potential to inhibit the activity of FREM1 and to prevent the development of cancer.

One potential drug target for FREM1 is the inhibitor of the protein kinase PDK4, which is a key regulator of cell proliferation. Researchers have shown that inhibiting PDK4 with the drug pidostigmabimab can inhibit the growth and spread of cancer cells. This suggests that FREM1 may be a useful target for cancer treatment.

Another potential drug target for FREM1 is the inhibitor of the protein tyrosine phosphatase Pyk2, which is involved in cell signaling pathways. Researchers have shown that inhibiting Pyk2 with the drug tyrosine can inhibit the growth and spread of tumor cells.

Biomarker Potential

FREM1 has also been shown to be a potential biomarker for certain diseases. For example, FREM1 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Researchers have shown that reducing FREM1 expression can protect against the development of neurodegenerative diseases.

FREM1 has also been shown to be involved in the development of certain cancers, such as breast cancer. Researchers have shown that increasing FREM1 expression can promote the growth and spread of breast cancer cells. This suggests that FREM1 may be a useful biomarker for breast cancer.

Conclusion

FREM1 is a protein that is involved in the regulation of cell division and cell signaling pathways. It has been shown to promote the G1 phase of the cell cycle and to inhibit the G2 phase. FREM1 has also been shown to be involved in the regulation of angiogenesis and the development of various diseases, including cancer. Therefore, FREM1 is a potential drug target for cancer treatment and a potential biomarker for certain diseases.

Protein Name: FRAS1 Related Extracellular Matrix 1

Functions: Extracellular matrix protein that plays a role in epidermal differentiation and is required for epidermal adhesion during embryonic development

The "FREM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FREM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets